SAGIMET BIOSCIENCES INC SERIES A (SGMT)
Health Care · Clinical-stage biopharmaceutical / metabolic and fibrotic disease therapeutics · NASDAQ
Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases.
What SAGIMET BIOSCIENCES INC SERIES A does
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases. The company's lead candidate, denifanstat, is an oral selective FASN inhibitor in Phase 2b development for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers. A second candidate, TVB-3567, is in development for acne. The company also develops combination therapies pairing denifanstat with existing drugs to address unmet medical needs.
Themes: MASH (metabolic dysfunction-associated steatohepatitis) / liver disease, Fatty acid synthase inhibition, Metabolic dysfunction / steatotic liver disease, Fibrosis regression / anti-fibrotic therapy, Acne treatment, Dermatology, Cancer (select forms)
Fundamentals
- Price$10.25 as of 2026-08-21 close
- Market cap$568M as of 2026-08-24
- 1-year return+39.5% 2025-08-21 close $7.35 → 2026-08-21 close $10.25
- P/En/a negative earnings
- Net margin-1393.8% as of 2026-08-24
- ROE-37.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta3.52 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How SGMT compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SAGIMET BIOSCIENCES INC SERIES A looks technically
SAGIMET BIOSCIENCES INC SERIES A (SGMT) is trading 51.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 51 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 51.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.88 | $7.88 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.75 | $6.75 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 51 trading days ago — a "golden cross", a bullish long-term signal | 51 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 37.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 69.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($7.15 to $11.15) — its "stochastic" reading is 78 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 77.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.15 | $11.15 |
|---|---|---|
| From the 52-week high | it is 8.1% below its 52-week high (its highest price of the past year) | -8.1% |
| Above the 52-week low | it is 127.8% above its 52-week low (its lowest price of the past year) | +127.8% |
| Below the 52-week high | it is 8.1% below its highest point of the past year | 8.1% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $20.71 (set on 2024-01-22) | $20.71 |
| Given back of the 52-week move | over the past year its closes ranged ($4.55 to $10.58), and it has given back only a small part of its rise from last year’s low — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.66 to $6.85. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.5% |
| From the all-time high | it is 50.5% below its all-time high | -50.5% |
| Nearest price level | it is trading 2.2% above a support level at $10.02 — a price it turned at twice since 2025-07-10, most recently on 2025-08-13. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.2% |
| All-time low | its lowest closing price on record is $1.73 (set on 2025-04-07) | $1.73 |
| Above the all-time low | it is 492.5% above its all-time low | +492.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 89% of the past ~6 months) | 89th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5887 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5887 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.32 and $11.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.32 – $8.90 – $11.49 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (51.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 9.2% since the prior reading | +9.2% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 42.6 percentage points (the stock gained 45.0% while the market gained 2.3%) | +42.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 43.3 percentage points (the stock gained 46.4% while the market gained 3.1%) | +43.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 81.6 percentage points (the stock gained 92.7% while the market gained 11.1%) | +81.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 19.0 percentage points (the stock gained 39.5% while the market gained 20.5%) | +19.0% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.9% of the share price. | +33.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 37% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.46 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +37.5% |
|---|
Price levels it has turned at before
SGMT last closed at $10.25 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.02 | Support | 2.2% below the last close | turned there twice · 2025-07-10 to 2025-08-13 |
| $9.41 | Support | 8.2% below the last close | turned there twice · 2025-10-27 to 2026-04-27 |
| $8.80 | Support | 14.2% below the last close | turned there twice · 2025-10-09 to 2025-11-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Printed a doji candle · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$28.60 range $8.00 – $56.00; median $28.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SGMT
- Consensus EPS estimate-$0.25 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial risk: denifanstat met Phase 2b primary endpoints in FASCINATE-2 but adverse event-driven discontinuation was 19.6% vs 5.4% placebo, creating safety tolerance risk in larger trials and commercial use","Regulatory and development uncertainty: company pursuing non-cirrhotic and cirrhotic MASH indications with no approved MASH therapeutics as benchmark; reliance on partnership with Ascletis for China development and non-dilutive funding for combination trials limits control","Financial runway and capital requirements: unprofitable clinical-stage company with negative 1393.8% net margin; successful development requires substantial additional capital for Phase 3 trials, manufacturing scale-up, and commercial launch"]
What changed in the latest 10-Q
AI-assisted comparison of SGMT's 10-Q filed 2026-05-12 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) adds that denifanstat met all endpoints in Ascletis' open-label Phase 3 clinical trial evaluating long-term safety in patients with moderate to severe acne in China
- Newer filing adds January 2026 announcement that Ascletis reported denifanstat was generally well-tolerated in open-label Phase 3 trial (n=240) with improvements in all efficacy endpoints measured at 52 weeks
- Newer filing adds December 2025 announcement that China NMPA accepted NDA for denifanstat for treatment of moderate to severe acne
- Newer filing adds section on 'Planned Phase 3 clinical trial of denifanstat in acne' describing plans to file IND application in mid-2026 and advance to Phase 3 trial in second half of 2026 for United States
- Newer filing adds statement that Phase 1 pharmacokinetic trial of denifanstat and resmetirom combination was completed in December 2025
- Newer filing adds statement that denifanstat and resmetirom combination program will be Phase 2-ready in second half of 2026
- Newer filing adds statement 'We will undertake no further clinical development in MASH until non-dilutive financing is obtained'
- Removed:
- Older filing (2025-11-13) states Phase 1 PK trial was initiated in September 2025; newer filing indicates it was completed in December 2025, removing the 'initiated' context
- Older filing describes announcement in October 2025 that Ascletis completed pre-NDA consultation with NMPA and plans to submit NDA soon; newer filing removes this and replaces with December 2025 announcement that NMPA accepted the NDA
- Older filing states 'We anticipate topline data from this Phase 1 PK trial to be available in the first half of 2026'; newer filing indicates trial is already completed (December 2025), so this forward-looking statement is removed
- Older filing contains discussion of Phase 1 PK trial objectives and preclinical synergy data; newer filing removes detailed description of trial structure and moves focus to completion status
- Reworded:
- Newer filing reorders denifanstat's development indications from 'MASH, acne, and select forms of cancer' (older) to 'acne, metabolic dysfunction-associated steatohepatitis (MASH) and select forms of cancer' (newer), with acne listed first
- Newer filing expands Overview section with dedicated subsection 'FASN inhibition for the treatment of acne' providing background on acne epidemiology and pathophysiology; older filing places acne discussion later
- Newer filing adds 'Clinical data demonstrates denifanstat's potential to treat acne' as new subsection header before clinical trial data
- Older filing's description of Phase 1 PK trial initiation ('In September 2025, we initiated') is replaced in newer filing with completion status ('We completed a Phase 1 pharmacokinetic (PK) clinical trial...in December 2025')
- Older filing states 'plan to use it to inform the optimal dose levels...in a Phase 2 combination proof-of-concept efficacy trial'; newer filing states program 'will be Phase 2-ready in the second half of 2026' with no further MASH development until financing obtained
- Notes:
- The older filing appears truncated at the end of the Phase 1 TVB-3567 section; comparison of complete sections is not possible for all content
- The newer filing's section on 'Components of results of operations' and 'Research and development expenses' is also truncated; full MD&A comparison cannot be completed
- Dates mentioned span from June 2024 (EASL Congress) through May 2026 (filing date); all temporal references are as stated in the source documents
Risk Factors
- Added:
- Added reference to 'registration efforts' for denifanstat in China in relation to Ascletis and Gannex (newer filing, 2026-05-12)
- Added 'non-dilutive' descriptor to funding mentioned for future clinical trials (newer filing, 2026-05-12)
- Added reference to 'combination of denifanstat and resmetirom' for MASH development (newer filing, 2026-05-12)
- Removed:
- Removed 'Phase 3' specification from clinical trials reference for denifanstat in MASH (older filing, 2025-11-13)
- Removed reference to 'grow a sales team' language replaced with 'build a commercial organization' (older filing, 2025-11-13)
- Reworded:
- Changed 'and needs for additional financing' to 'and needs for additional financing' with comma placement adjustment (minimal change, 2026-05-12)
- Changed 'success of their development efforts for denifanstat in China' to 'success of their development and registration efforts for denifanstat in China' (newer filing, 2026-05-12)
- Changed 'our ability to grow a sales team' to 'our ability to build a commercial organization' (newer filing, 2026-05-12)
- Changed 'our ability to obtain sufficient funding' to 'our ability to obtain sufficient non-dilutive funding' (newer filing, 2026-05-12)
- Changed 'initiate Phase 3 clinical trials for denifanstat in MASH' to 'initiate future clinical trials for our combination of denifanstat and resmetirom in MASH' (newer filing, 2026-05-12)
- Changed reference year from '2024' to '2025' for Annual Report on Form 10-K (newer filing, 2026-05-12)
- Notes:
- Both texts appear truncated at the end; comparison based on available portions only
- Item number references differ between filings (27 in newer vs. 30 in older), but this reflects table of contents pagination, not substantive content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($4M) — 1 selling insider
- Last 90 days0 buys · 5 sells ($5M) — 3 selling insiders
- Last 180 days0 buys · 5 sells ($5M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-14. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SGMT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SGMT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,765,121
- Reported value $9,222,759
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SGMT had 11,595,503 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for SGMT because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 11,595,503
- Prior settlement (shares) 9,743,203
- Reported change 19.01%
- Days to cover (reported) 16.31
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD) - MASH pipeline including resmetirom (Rezdiffra)
- Eli Lilly (LLY) - GLP-1 receptor agonists and MASH development
- Viking Therapeutics - GLP-1/GCG receptor agonist for metabolic disease
- Novo Nordisk (NVO) - GLP-1 receptor agonists
- Madrigal Pharmaceuticals (formerly Intercept Biosciences) - obeticholic acid for MASH
- Rgenix (private) - MASH therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SGMT vs…
Frequently asked questions
What does SAGIMET BIOSCIENCES INC SERIES A (SGMT) do?
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases. The company's lead candidate, denifanstat, is an oral selective FASN inhibitor in Phase 2b development for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers. A second candidate, TVB-3567, is in development for acne.
What sector is SAGIMET BIOSCIENCES INC SERIES A (SGMT) in?
SAGIMET BIOSCIENCES INC SERIES A (SGMT) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical / metabolic and fibrotic disease therapeutics. It trades on NASDAQ.
Who are SAGIMET BIOSCIENCES INC SERIES A's (SGMT) competitors?
Notable peers of SAGIMET BIOSCIENCES INC SERIES A (SGMT) include Gilead Sciences (GILD) - MASH pipeline including resmetirom (Rezdiffra), Eli Lilly (LLY) - GLP-1 receptor agonists and MASH development, Viking Therapeutics (VKING) - GLP-1/GCG receptor agonist for metabolic disease, Novo Nordisk (NVO) - GLP-1 receptor agonists and Madrigal Pharmaceuticals (formerly Intercept Biosciences) - obeticholic acid for MASH. This peer set is informational only — not financial advice.
Is SAGIMET BIOSCIENCES INC SERIES A (SGMT) overbought or oversold right now?
SAGIMET BIOSCIENCES INC SERIES A (SGMT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SGMT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.